Heart & blood Lipopeptide antifungals
Echinocandins
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- FDA approval
- An FDA-approved product contains this peptide
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
The echinocandins (caspofungin, micafungin, and anidulafungin; sold as Cancidas, Mycamine, and Eraxis) are antifungal lipopeptides that attack the fungal cell wall, a structure human cells lack. They are a preferred option for invasive Candida infections and are generally well tolerated. All three have been FDA-approved in the U.S. since the 2000s, a fourth (rezafungin, sold as Rezzayo) was approved in 2023, and all are given intravenously.
At a glance
- What they are
- Echinocandin antifungal lipopeptides that block fungal cell-wall synthesis
- Approved for
- Invasive candidiasis and candidemia, esophageal candidiasis, and (caspofungin) some aspergillosis and febrile neutropenia
- Key fact
- Caspofungin was at least as effective as amphotericin B for invasive candidiasis, with fewer side effects
- Route
- Intravenous
- Evidence strength
- FDA approved
Summary
Echinocandins are FDA-approved antifungal lipopeptides that block the fungal cell wall. Learn how caspofungin, micafungin, and anidulafungin work and are used.
What are the echinocandins?
The echinocandins are a class of antifungal drugs, semi-synthetic cyclic lipopeptides, that includes caspofungin (Cancidas), micafungin (Mycamine), and anidulafungin (Eraxis). They are used mainly for serious Candida infections and have become a preferred option because they combine strong activity with a clean safety profile. Caspofungin, the first in the class, was approved in the United States in 2001, followed by micafungin in 2005 and anidulafungin in 2006. A newer member of the class, rezafungin (Rezzayo), was approved in 2023 and is given once a week.
How do they work?
Echinocandins target the fungal cell wall, specifically the enzyme 1,3-beta-D-glucan synthase. This enzyme builds 1,3-beta-D-glucan, a structural sugar polymer that gives the fungal wall its integrity. By blocking it, echinocandins weaken the wall until the fungal cell can no longer withstand internal pressure and ruptures. They are fungicidal against most Candida species and fungistatic against Aspergillus.
A key advantage is selectivity: human cells have no cell wall and no equivalent of this enzyme, so echinocandins cause relatively little direct toxicity to the patient. Caspofungin, micafungin, and anidulafungin are given intravenously once daily, and rezafungin once weekly. In its pivotal trial, caspofungin was at least as effective as amphotericin B for invasive candidiasis while causing fewer adverse effects, and anidulafungin outperformed fluconazole on the primary measure in its own trial.
Is it FDA-approved?
Editor’s note
Status: Yes. Caspofungin, micafungin, and anidulafungin are all FDA-approved, as is rezafungin; the table shows each one's approval year and approved uses. Drug | FDA approval | Approved uses include Caspofungin | 2001 | Candidemia, invasive candidiasis, and esophageal candidiasis; additionally, empiric therapy in febrile neutropenia and invasive aspergillosis refractory to or intolerant of other therapy Micafungin | 2005 | Candidemia, invasive candidiasis, and esophageal candidiasis; additionally, Candida prophylaxis in stem-cell transplant recipients Anidulafungin | 2006 | Candidemia, invasive candidiasis, and esophageal candidiasis Rezafungin | 2023 | Candidemia and invasive candidiasis in adults with limited or no other treatment options None carry a boxed warning.
Category: FDA-approved · Primary body area: Heart & blood
Yes. Caspofungin, micafungin, and anidulafungin are all FDA-approved, as is rezafungin; the table shows each one's approval year and approved uses.
| Drug | FDA approval | Approved uses include |
|---|---|---|
| Caspofungin | 2001 | Candidemia, invasive candidiasis, and esophageal candidiasis; additionally, empiric therapy in febrile neutropenia and invasive aspergillosis refractory to or intolerant of other therapy |
| Micafungin | 2005 | Candidemia, invasive candidiasis, and esophageal candidiasis; additionally, Candida prophylaxis in stem-cell transplant recipients |
| Anidulafungin | 2006 | Candidemia, invasive candidiasis, and esophageal candidiasis |
| Rezafungin | 2023 | Candidemia and invasive candidiasis in adults with limited or no other treatment options |
None carry a boxed warning.
What are they prescribed for?
Echinocandins are prescribed for invasive Candida infections, including candidemia, and for esophageal candidiasis. Caspofungin is also used for suspected fungal infection in neutropenic fever and for certain Aspergillus infections, and micafungin for preventing Candida infection during stem-cell transplantation.
What are the side effects?
Common side effects include:
- Fever
- Infusion-related reactions such as flushing, rash, or itching
- Nausea and headache
- Low potassium and raised liver enzymes
More serious considerations include:
- Liver effects and, rarely, more significant liver dysfunction
- Rare severe allergic reactions
- Dose adjustment for caspofungin in liver impairment and some drug interactions
Sources: FDA prescribing information for Cancidas, Mycamine, Eraxis, and Rezzayo; the caspofungin trial (Mora-Duarte et al., The New England Journal of Medicine, 2002, DOI: 10.1056/NEJMoa021585) and the anidulafungin trial (Reboli et al., The New England Journal of Medicine, 2007, DOI: 10.1056/NEJMoa066906), both indexed on PubMed. This document is educational and does not constitute medical advice.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
Compare every peptide’s status in the peptide regulatory status database
More for Heart & blood
View all heart & blood peptides →- FDA-approved Heart & blood
Angiotensin-Ii
Angiotensin II is a natural peptide hormone and the main active signal of the renin-angiotensin system, which the body uses to raise blood pressure by tightening blood vessels. A synthetic version is FDA-approved as Giapreza, an intravenous drug given in intensive care to raise dangerously low blood pressure in adults with septic or other distributive shock. In its pivotal ATHOS-3 trial it raised blood pressure in about 70% of patients compared with 23% on placebo, though it also carries a risk of blood clots.
- In clinical trials Heart & blood
Balixafortide
Balixafortide is an investigational peptide that blocks the CXCR4 receptor, studied by Polyphor in combination with chemotherapy for metastatic breast cancer. An early single-arm trial suggested activity, but the pivotal Phase 3 trial did not show a benefit over chemotherapy alone, and development has effectively stopped. As of 2026 it is not approved.
- FDA-approved Heart & blood
Bivalirudin
Bivalirudin is a synthetic 20-amino acid peptide anticoagulant, derived in design from the leech protein hirudin, that directly and reversibly blocks thrombin, the central enzyme in blood clotting. Sold as Angiomax, it is given intravenously during coronary procedures such as angioplasty and stenting to prevent clots, including in people who cannot receive heparin. In a large trial of heart-attack patients, using it instead of heparin plus a second blood thinner reduced major bleeding and lowered 30-day death rates.
- FDA-approved Heart & blood
Desirudin
Desirudin (formerly sold as Iprivask) is a recombinant form of hirudin, the natural anticoagulant from the medicinal leech, that was used to prevent blood clots after hip replacement surgery. It directly and specifically blocks thrombin, the central enzyme of the clotting cascade. It was FDA-approved in the U.S. in 2003, but Iprivask has since been discontinued and no desirudin product is currently sold in the U.S.
- FDA-approved Heart & blood
Desmopressin
Desmopressin (desmopressin acetate; brands include DDAVP and Nocdurna) is a synthetic version of the antidiuretic hormone vasopressin, engineered to concentrate urine without raising blood pressure. It treats central diabetes insipidus, bedwetting, nighttime urination, and certain bleeding disorders. It has been FDA-approved in the U.S. since 1978 and comes as tablets, a sublingual form, nasal spray, and injection.
- FDA-approved Heart & blood
Eptifibatide
Eptifibatide (sold as Integrilin) is a small cyclic peptide, modeled on a molecule from rattlesnake venom, that blocks the final step of platelet clumping to prevent dangerous clots during heart attacks and stenting. It is given intravenously in acute coronary syndrome and during coronary procedures. It has been FDA-approved in the U.S. since 1998, and its main risk is bleeding.